Skip to main content

Orphazyme A/S (ORPH)

NASDAQ: ORPH · IEX Real-Time Price · USD
4.00
+0.05 (1.27%)
After-hours:Oct 22, 2021 7:57 PM EDT
3.95
-0.17 (-4.13%)
At close: Oct 22, 4:00 PM
Market Cap140.43M
Revenue (ttm)13.15M
Net Income (ttm)n/a
Shares Out34.95M
EPS (ttm)-4.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,578,067
Open4.06
Previous Close4.12
Day's Range3.85 - 4.10
52-Week Range3.78 - 77.77
Beta0.70
AnalystsStrong Buy
Price Target21.15 (+435.5%)
Est. Earnings Daten/a

About ORPH

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, In...

IndustryBiotechnology
IPO DateSep 29, 2020
CEOKim Stratton
Employees180
Stock ExchangeNASDAQ
Ticker SymbolORPH
Full Company Profile

Financial Performance

Financial numbers in millions DKKFinancial Statements

Analyst Forecast

According to 3 analysts, the average rating for Orphazyme stock is "Strong Buy." The 12-month stock price forecast is 21.15, which is an increase of 435.50% from the latest price.

Price Target
$21.15
(435.50% upside)
Analyst Consensus: Strong Buy

News

Bank Stocks: Why BAC, WFC and MS Investors Are Smiling Today

Bank stocks are on the move Thursday following the release of earnings reports from various companies and we've got the details. The post Bank Stocks: Why BAC, WFC and MS Investors Are Smiling Today app...

Other symbols:AVDXBACMSWFC
1 week ago - InvestorPlace

ORPH Stock Alert: What's Going on With Red-Hot Orphazyme Today?

Today, retail investors and traders appear willing to put some big money down on Orphazyme and ORPH stock as a potential short-squeeze play. The post ORPH Stock Alert: What's Going on With Red-Hot Orpha...

1 week ago - InvestorPlace

Orphazyme provides regulatory and financial updates

Orphazyme A/SCompany announcement        No. 22/2021Company Registration No. 32266355

2 weeks ago - GlobeNewsWire

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourag...

LOS ANGELES, Sept. 7, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S ("Orphazyme" or "the C...

1 month ago - PRNewsWire

ORPH Final Deadline Today: Rosen, Leading Trial Attorneys, Encourages Orphazyme A/S Investors with Losses in Excess o...

New York, New York--(Newsfile Corp. - September 7, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/...

1 month ago - Newsfile Corp

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encou...

Los Angeles, California--(Newsfile Corp. - September 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S (...

1 month ago - Newsfile Corp

Final Deadline for Investors with Losses Exceeding $500K to Actively Participate in the Orphazyme A/S (ORPH) Class Ac...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or "the Company") (NA...

1 month ago - Business Wire

ORPH Final Deadline Tomorrow: Rosen, Top Ranked Global Counsel, Encourages Orphazyme A/S Investors with Losses to Sec...

New York, New York--(Newsfile Corp. - September 6, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/...

1 month ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Orphazyme A/S of Class ...

NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH) and certain of its officers...

1 month ago - PRNewsWire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme ...

LOS ANGELES--(BUSINESS WIRE)---- $ORPH #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)

1 month ago - Business Wire

TUESDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and...

Los Angeles, California--(Newsfile Corp. - September 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S (...

1 month ago - Newsfile Corp

TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S a...

Los Angeles, California--(Newsfile Corp. - September 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S (...

1 month ago - Newsfile Corp

Orphazyme reports business highlights and financial results in Interim Report First Half 2021

Orphazyme A/SCompany announcement No. 21/2021CVR No.: 32266355

1 month ago - GlobeNewsWire

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Importa...

NEW YORK, Aug. 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or traceable to Orp...

1 month ago - PRNewsWire

Orphazyme to host Interim Report First Half 2021 investor call on August 31, 2021

Orphazyme A/SInvestor news        No. 08/2021Company Registration No. 32266355

1 month ago - GlobeNewsWire

CytRx Highlights Orphazyme's Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerativ...

1 month ago - Business Wire

Dear ORPH Stock Fans, Here Is the Latest Trial News You Should Be Cheering

Today, ORPH stock is trading significantly higher after the company announced some positive clinical trial data for its lead drug candidate. The post Dear ORPH Stock Fans, Here Is the Latest Trial News ...

1 month ago - InvestorPlace

Investors React Positively To Data From Orphazyme's Neurodegenerative Disease Candidate

Orphazyme A/S (NASDAQ: ORPH) announced that results from a Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C (NPC) had been published in the peer-reviewed Journal of Inherited Metabolic Dise...

1 month ago - Benzinga

Orphazyme announces publication of results from its Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C in ...

Orphazyme A/SInvestor news No. 07/2021Company Registration No. 32266355

1 month ago - GlobeNewsWire

Rosen, A Leading Law Firm, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before...

New York, New York--(Newsfile Corp. - August 20, 2021) - WHY: New York, N.Y., August 20, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (N...

2 months ago - Newsfile Corp

ORPH NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Orphazyme A/S Investors with Losses in Excess of $100K ...

NEW YORK, Aug. 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or traceable to Orp...

2 months ago - PRNewsWire

Rosen, Top Ranked Investor Counsel, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important...

New York, New York--(Newsfile Corp. - August 14, 2021) - WHY:. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/o...

2 months ago - Newsfile Corp

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit A...

BENSALEM, Pa., Aug. 13, 2021 /PRNewswire/ -- Law Offices of Howard G.

2 months ago - PRNewsWire

CytRx Comments on Quarterly Results and Recent Strategic Initiatives

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerativ...

Other symbols:IBRX
2 months ago - Business Wire

What's Next For Orphazyme Stock?

Orphazyme A S ADR (NASDAQ: ORPH) shares are higher Wednesday, as traders were able to push the stock up. There looks to be no company-specific news to cause the jump in share price.

2 months ago - Benzinga